Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Viale Cappuccini 1, San Giovanni Rotondo, Italy.
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S34-41. doi: 10.1016/S0305-7372(10)70018-9.
Many patients with early-stage colon cancer are cured with surgery alone, even if the standard of care remains an uniform approach to adjuvant chemotherapy based primarily on tumour stage. Consequently, it is important to individualize decision-making in this subset of patients with the aim to identify potential prognostic and predictive markers in colon cancer. While 5-fluorouracil, leucovorin, and oxaliplatin are widely known as gold treatment in the post-operative of stage III, well-validated molecular markers might help define which patients with stage II disease are likely to benefit from adjuvant therapy as well. Herein we review the use of adjuvant chemotherapy in colon cancer and analyzed the date on the clinical development of molecular markers to individualize another therapeutic approach in colon cancer.
许多早期结肠癌患者仅通过手术即可治愈，即使标准治疗仍然是基于肿瘤分期的主要辅助化疗的统一方法。因此，重要的是要对这部分患者进行个体化决策，以确定结肠癌潜在的预后和预测标志物。虽然氟尿嘧啶、亚叶酸钙和奥沙利铂被广泛认为是 III 期术后的黄金治疗方法，但经过充分验证的分子标志物可能有助于确定哪些 II 期疾病患者可能受益于辅助治疗。本文综述了辅助化疗在结肠癌中的应用，并分析了分子标志物临床开发的数据，以实现结肠癌另一种治疗方法的个体化。
